NCT00317798View on ClinicalTrials.gov

Antithymocyte Globulin and Sirolimus in Treating Patients With Relapsed Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2011

Conditions
Drug/Agent Toxicity by Tissue/OrganMultiple Myeloma and Plasma Cell Neoplasm
Interventions
BIOLOGICAL

anti-thymocyte globulin

Escalating doses of rATG,intravenously, starting at 6 mg/kg to a maximum of 14.5 mg/kg. Rapamycin is given orally, starting at a dose of 1 mg daily beginning on day 1 and terminating on day 30. The dose of rapamycin was adjusted to maintain a constant blood level of 4-6 ng/ml in all subjects

DRUG

sirolimus

escalating doses of rATG, intravenously, starting at 6 mg/kg to a maximum of 14.5 mg/kg. Rapamycin is given orally, starting at a dose of 1 mg daily beginning on day 1 and terminating on day 30. The dose of rapamycin was adjusted to maintain a constant blood level of 4-6 ng/ml in all subjects

Trial Locations (1)

14642

James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester

All Listed Sponsors
lead

University of Rochester

OTHER

NCT00317798 - Antithymocyte Globulin and Sirolimus in Treating Patients With Relapsed Multiple Myeloma | Biotech Hunter | Biotech Hunter